Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Rheumatology|April 3, 2019
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab TrialsIain B McInnes, Lluís Puig, Alice B Gottlieb, et al.Journal of Environmental Management|February 13, 2026
A comprehensive review on applications of covalent organic frameworks (COFs) for pesticide controlWeixia Yang, Yuqing Liu, Shiman Wang, et al.Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.RMD Open|March 27, 2020
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trialsPhilip S Helliwell, Dafna D Gladman, Soumya D Chakravarty, et al.Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.Pageof 3